CalciMedica (NASDAQ:CALC) Stock Falls 16.6% – Should You Sell?

CalciMedica Inc. (NASDAQ:CALC) shares traded down 16.6% during trading on Friday. The company traded as low as $1.44 and last traded at $1.46. Approximately 103,064 shares traded hands during mid-day trading, an increase of 19% from the average session volume of 86,728 shares. The stock had previously closed at $1.75.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Wall Street Zen downgraded CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. Guggenheim initiated coverage on CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating on the stock. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, UBS Group reissued a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CalciMedica currently has a consensus rating of “Hold” and a consensus price target of $50.00.

CalciMedica Stock Performance

The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The stock’s 50-day moving average price is $1.76 and its 200-day moving average price is $4.27. The company has a market cap of $9.97 million, a P/E ratio of -0.21 and a beta of 0.76.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. Equities analysts anticipate that CalciMedica Inc. will post -5.25 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in CalciMedica stock. 180 Wealth Advisors LLC increased its holdings in CalciMedica Inc. (NASDAQ:CALC) by 297.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,500 shares of the company’s stock after buying an additional 94,650 shares during the period. 180 Wealth Advisors LLC owned 0.80% of CalciMedica worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

About CalciMedica

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.